You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Starting Oct. 1, the insurer will require clinicians and labs who order genetic and molecular tests for their patients to first get approval.
The test is now covered by Premera Blue Cross, a regional health plan with more than 2 million members located primarily in Washington, Oregon, and Alaska.
The long-term pricing contract covers hereditary cancer testing, GeneSight, and a number of other diagnostics, but doesn't extend to coverage.
The company said the number of lives now covered for EndoPredict has gone up to 109 million.
Winship's director of the cancer tissue and pathology shared resource said that some labs aren't leveraging molecular technologies due to reimbursement issues.
The company said it now has payor coverage for more than 130 million individuals.
The company obtained out-of-state provider status from California's Medicaid program for its OVA1 test, giving it access to more than 12 million patients.
The firm said that the new coverage for its Afirma thyroid cancer test makes it a medically necessary benefit for nearly 24 million Blues plan members.
Starting Feb. 15, Aetna members will be able to access NxGen MDx's genetic screening and noninvasive prenatal testing as an in-network benefit.
The coverage decision provides Humana's 13 million members with access to the test, which provides a numerical score to assess the risk of disease recurrence.
Italy has held talks with vaccine developers to manufacture mRNA-based SARS-CoV-2 vaccines, according to the Financial Times.
The Associated Press reports US officials are removing restrictions on fetal tissue research that were added during the Trump Administration.
The Biden Administration is investing $1.7 billion to detect and monitor SARS-CoV-2 variants.
In PLOS this week: genome instability in Aicardi-Goutières Syndrome, introduction of SARS-CoV-2 to the Colombian Amazon, and more.